Mod GRF, GHRP-2 10mg (Blend) — Dual-Action Growth Hormone Secretagogue Research Formulation
This advanced 10mg synergistic formulation pairs Mod GRF (1-29) (Modified Growth Hormone-Releasing Factor) with GHRP-2 (Growth Hormone Releasing Peptide-2) to deliver a highly optimized, dual-mechanism architecture for neuroendocrine research. By combining a stabilized Growth Hormone-Releasing Hormone (GHRH) analogue with a highly selective and potent Growth Hormone Secretagogue Receptor (GHSR) agonist, this blend allows investigators to explore highly amplified, pulsatile release pathways of endogenous growth hormone.
-
Dual-Pathway Signaling Synergy: Simultaneously targets distinct pituitary receptor configurations. Mod GRF (1-29) acts directly on GHRH receptors, while GHRP-2 binds to the ghrelin/secretagogue receptors to actively suppress somatostatin, evaluating an optimized and highly efficient cellular signaling cascade.
-
Refined Physiological Profile: Engineered to study growth hormone secretagogue interactions with a lower impact on appetite-stimulating signaling pathways compared to earlier generations, allowing for precise metabolic baselines.
-
Key Research Areas: Extensively utilized in metabolic, physiological, and endocrinological studies to investigate lean tissue preservation, visceral adipose tissue reduction, cellular repair mechanisms, and physiological feedback loops.
-
Purity Guaranteed: purity of each constituent peptide within the blend, verified by rigorous HPLC and Mass Spectrometry testing to maintain exact and repeatable experimental baselines.
-
Optimal Stability: Supplied as a sterile, lyophilized powder format to protect delicate peptide chains, ensuring excellent structural integrity and straightforward reconstitution for in vitro and laboratory assays.
Note: This product is sold strictly as a high-purity research chemical. It is intended solely for laboratory, in vitro, or animal research applications and is not approved for human injection, therapeutic, or diagnostic use.



